ADDERALL XR

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales . Revenue Guidance Upgrade July 31 2008

As a result of the launch of VYVANSE in July 2007, ADDERALL XR's average quarterly market share of the US ADHD market for Q2 2008 fell to 23.1% (2007: 26.3%), a decrease of 12% compared to Q2 07. US prescriptions for ADDERALL XR for the period to June 30, 2008 decreased by 6% compared to the same period in 2007 due to the 12% decrease in average market share offset by 7% growth in the US ADHD market. Sales of ADDERALL XR for the three months to June 30, 2008 were $296.4 million.

Headliner: Shire's Angus Russell August 18, 2008
Total revenues for Q2 were up 35% to $776 million, but there's been a lot of talk about how it will cope with generic competition next year on ADHD drug Adderall XR. Last summer, Shire launched the pediatric indication of Vyvanse, a new class of ADHD drug, which is currently the number three ADHD brand with sales over $325 million since launch. Many Adderall XR patients are transitioning to Vyvanse.

Shire's Vyvanse forecast disappoints April 25, 2008
Based on existing prescription trends and the recently received approval for the adult indication, we expect Vyvanse sales to be at the lower end of the previously stated range of $350 (176 pounds) to $400 million. The U.S. ADHD market was growing around 6-7 percent and expected this to accelerate after Shire started promoting Vyvanse to adults. Vyvanse sales totalled $54.4 million, while Adderall XR sales rose 5 percent to $261.5 million.

http://www.zhion.com/drug/Adderall.html